You searched for "therapy"

336 results found

Can you boost your bladder with vitamin D?

Bladder overactivity is a common problem affecting the social functioning of children. Overactive bladder dry (OAB-dry) is a term (one not utilised by the International Children’s Continence Society) and refers to patients who are experiencing frequency, urgency and nocturia symptoms...

Focal therapies in prostate cancer

The standard of care in the management of prostate cancer has, to date, always been to treat the whole gland. This has ranged from surveillance, surgical excision / prostatectomy or external beam radiotherapy / whole gland brachytherapy. With the evolution...

Call for standardised reporting of adverse events

This article will be of immense benefit to all of us involved in mortality and morbidity meetings and Clinical Governance, especially registrars and junior members of the team. The authors present data from the UK, USA and Europe. In prostate...

How effective are intravesical therapies for bladder pain syndrome?

The objective of this study was to review the clinical efficacy of currently available products for the intravesical treatment of bladder pain syndrome (BPS) / interstitial cystitis (IC) and to assess their pharmaco-economic impact. Nineteen articles were reviewed, including five...

Oestrogens and OAB

This is a multicentre study from Europe. The female genitals and lower urinary tract have a common embryological origin arising from urogenital sinus. Therefore, both could be sensitive to female sex steroid hormones. Oestrogens and progesterone receptors have been demonstrated...

An overview of non-surgical treatment options for Peyronie’s disease

Peyronie’s disease (PD) is a therapeutic challenge despite the availability of several non-surgical and surgical options. Very few of these options are supported by good quality evidence according to the current American and European guidelines [1-3]. The period of plaque...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

New drug hope for prostate cancer patients

• Hormone therapy is used to slow the progression of advanced prostate cancer, but cancers often develop resistance and continue to grow.• Research reveals that patients with higher levels of heat shock proteins have worse outcomes.• Targeting these proteins with...

Recurrent urinary tract infections in women

This review article defined women who had recurrent urinary tract infections (UTIs) as having either ≥ two episodes in the last six months or ≥ three episodes in the last 12 months. Using a number of databases, including the Cochrane...

Adjuvant radiotherapy versus wait-and-see after radical prostatectomy

Optimum treatment modalities in prostate cancer continue to evolve, with debates at each stage of the evolution process, from focal therapy to radical treatment. In this randomised study, Wiegel et al. investigated the role of adjuvant radiotherapy following open radical...

Vitamin B12 deficiency in patients after enterocystoplasty

It is well known that enterocystoplasty within terminal ileum leads to vitamin B12 deficiency and regular monitoring of this post-surgery is essential. Often supplements need to be given because of deficiency in up to 40% of patients. These authors looked...

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...